Biohaven Stock Heads for Best Day in 3 Years as FDA Agrees to Review Drug AgainBarrons · 2 days ago
Biohaven Rebounds With FDA Review Date for Rare Disease DrugBenzinga · 2 days ago
Biohaven Expands Asian Licensing Footprint Through Strategic Ono AgreementBenzinga · Oct 8, 2026
Biohaven Enters Strategic Licensing Agreement with Ono Pharma for Extracellular IgG Degraders in Japan and Select Asian Regions, Lead Candidate BHV-1300 in Phase 3 for Graves' DiseaseGuruFocus · Oct 8, 2026
Biohaven Enters Strategic Licensing Agreement with Ono Pharma for Extracellular IgG Degraders in Japan and Select Asian Regions, Lead Candidate BHV-1300 in Phase 3 for Graves' DiseasePRNewsWire · Oct 8, 2026
Biohaven's Clinical Data on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload, Selected for Oral Presentation at the EORTC-NCI-AACR Symposium 2026GuruFocus · Sep 28, 2026Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity. The company is also developing BHV-1510 that is in Phase 2 clinical trial for the treatment of advanced or metastatic epithelial tumors; and BHV-1530, which is in Phase 2 clinical trial for treating urothelial cancer and other tumors.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 10, 2026 | -$0.76 | -$0.91 | Miss |
| May 4, 2026 | -$0.86 | -$0.88 | Miss |
| Mar 2, 2026 | -$1.22 | -$1.21 | Beat |
| Nov 10, 2025 | -$1.91 | -$1.64 | Beat |
| Aug 11, 2025 | -$1.94 | -$1.94 | Beat |
| May 12, 2025 | -$1.67 | -$2.17 | Miss |